SC 13D/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

§ 240.13d-2(a)

(Amendment No. 1)1

Celera Corporation

(Name of Issuer)

Common Stock, par value $0.01

(Title of Class of Securities)

15100E106

(CUSIP Number)

ELIZABETH DELANEY

BVF PARTNERS L.P.

900 North Michigan Avenue

Suite 1100

Chicago, Illinois 60611

(312) 506-6500

ADAM W. FINERMAN, ESQ.

OLSHAN GRUNDMAN FROME ROSENZWEIG & WOLOSKY LLP

Park Avenue Tower

65 East 55th Street

New York, New York 10022

(212) 451-2300

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

April 4, 2011

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

_______________

1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP NO. 15100E106

1	NAME OF REPORTING PERSON BIOTECHNOLOGY VALUE FUND, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) x   (b) o
3	SEC USE ONLY
4	SOURCE OF FUNDS WC
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)		¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER - 0 -
	8	SHARED VOTING POWER 2,268,392
	9	SOLE DISPOSITIVE POWER - 0 -
	10	SHARED DISPOSITIVE POWER 2,268,392
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,268,392
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 2.8%
14	TYPE OF REPORTING PERSON PN

2

CUSIP NO. 15100E106

1	NAME OF REPORTING PERSON BIOTECHNOLOGY VALUE FUND II, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) x   (b) o
3	SEC USE ONLY
4	SOURCE OF FUNDS WC
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)		¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER - 0 -
	8	SHARED VOTING POWER 1,571,000
	9	SOLE DISPOSITIVE POWER - 0 -
	10	SHARED DISPOSITIVE POWER 1,571,000
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,571,000
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 1.9%
14	TYPE OF REPORTING PERSON PN

3

CUSIP NO. 15100E106

1	NAME OF REPORTING PERSON BVF INVESTMENTS, L.L.C.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) x   (b) o
3	SEC USE ONLY
4	SOURCE OF FUNDS WC
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)		¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER - 0 -
	8	SHARED VOTING POWER 5,449,000
	9	SOLE DISPOSITIVE POWER - 0 -
	10	SHARED DISPOSITIVE POWER 5,449,000
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,449,000
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.6%
14	TYPE OF REPORTING PERSON OO

4

CUSIP NO. 15100E106

1	NAME OF REPORTING PERSON INVESTMENT 10, L.L.C.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) x   (b) o
3	SEC USE ONLY
4	SOURCE OF FUNDS WC
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)		¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION ILLINOIS
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER - 0 -
	8	SHARED VOTING POWER 567,000
	9	SOLE DISPOSITIVE POWER - 0 -
	10	SHARED DISPOSITIVE POWER 567,000
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 567,000
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) Less than 1%
14	TYPE OF REPORTING PERSON OO

5

CUSIP NO. 15100E106

1	NAME OF REPORTING PERSON BVF PARTNERS L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) x   (b) o
3	SEC USE ONLY
4	SOURCE OF FUNDS AF
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)		¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER - 0 -
	8	SHARED VOTING POWER 9,855,392
	9	SOLE DISPOSITIVE POWER - 0 -
	10	SHARED DISPOSITIVE POWER 9,855,392
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,855,392
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 12.0%
14	TYPE OF REPORTING PERSON PN, IA

6

CUSIP NO. 15100E106

1	NAME OF REPORTING PERSON BVF INC.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) x   (b) o
3	SEC USE ONLY
4	SOURCE OF FUNDS AF
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)		¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER - 0 -
	8	SHARED VOTING POWER 9,855,392
	9	SOLE DISPOSITIVE POWER - 0 -
	10	SHARED DISPOSITIVE POWER 9,855,392
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,855,392
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 12.0%
14	TYPE OF REPORTING PERSON CO

7

CUSIP NO. 15100E106

1	NAME OF REPORTING PERSON MARK N. LAMPERT
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) x   (b) o
3	SEC USE ONLY
4	SOURCE OF FUNDS AF
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)		¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION USA
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER - 0 -
	8	SHARED VOTING POWER 9,855,392
	9	SOLE DISPOSITIVE POWER - 0 -
	10	SHARED DISPOSITIVE POWER 9,855,392
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,855,392
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 12.0%
14	TYPE OF REPORTING PERSON IN

8

CUSIP NO. 15100E106

The following constitutes Amendment No. 1 to the Schedule 13D filed by the undersigned (“Amendment No. 1”).  This Amendment No. 1 amends the Schedule 13D as specifically set forth herein.

Item 4. Purpose of Transaction

Item 4 is hereby amended to add the following:

On March 18, 2011, the Issuer announced that it had entered into an agreement and plan of merger (the “Merger”) with Quest Diagnostics Incorporated (“Quest”) and Spark Acquisition Corporation, a wholly owned subsidiary of Quest (the “Purchaser”), pursuant to which the Purchaser will commence a tender offer to acquire all of the issued and outstanding Shares for $8.00 per Share, net to the holder thereof in cash (the “Offer Price”).

On March 30, 2011, the Reporting Persons sent a letter to the CEO of Quest, Dr. Surya N. Mohapatra, Ph.D., stating that the Reporting Persons believe that the extraordinary value of the Issuer’s passive drug royalties were not reflected in the Offer Price and that the Merger should be restructured to carve out these non-strategic drug royalties.  The Reporting Persons believe a cooperative solution is in the best interest of all parties, including Quest, certainly relative to non-cooperative alternatives.

The letter further stated that should Quest and the Issuer be unwilling to restructure the Merger, the Reporting Persons intend to (1) not tender their shares in the Merger and would encourage all shareholders to do the same; (2) continue discussions with third-parties regarding alternatives to the Merger including, but not limited to, the submission of a superior proposal for all or part of the Issuer and/or the replacement of the Issuer’s management; and (3) in the event that the majority of Shares are tendered and the Merger is approved, seek appraisal rights for its Shares and encourage all non-tendering shareholders to do the same.  A copy of the letter is attached as Exhibit 99.1 hereto and incorporated herein by reference.

On April 1, 2011, Quest responded to the letter, rejecting the Reporting Persons’ proposal.  A copy of Quest’s response is attached as Exhibit 99.2 hereto and incorporated herein by reference.

Item 7. Material to be Filed as Exhibits.

Item 7 is hereby amended to add the following exhibits:

99.1 Letter from Biotechnology Value Fund, L.P. to Quest Diagnostics, Incorporated, dated March 30, 2011.

99.2 Letter from Quest Diagnostics, Incorporated to Biotechnology Value Fund, L.P., dated April 1, 2011.

9

CUSIP NO. 15100E106

SIGNATURES

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated:  April 4, 2011
BIOTECHNOLOGY VALUE FUND, L.P.		INVESTMENT 10, L.L.C.
By:	BVF Partners L.P., its general partner	By:	BVF Partners L.P., its investment manager
By:	BVF Inc., its general partner	By:	BVF Inc., its general partner
By:	/s/ Mark N. Lampert	By:	/s/ Mark N. Lampert
	Mark N. Lampert		Mark N. Lampert
	President		President
BIOTECHNOLOGY VALUE FUND II, L.P.		BVF PARTNERS L.P.
By:	BVF Partners L.P., its general partner	By:	BVF Inc., its general partner
By:	BVF Inc., its general partner	By:	/s/ Mark N. Lampert
			Mark N. Lampert
By:	/s/ Mark N. Lampert		President
	Mark N. Lampert
	President
		BVF INC.
BVF INVESTMENTS, L.L.C.		By:	/s/ Mark N. Lampert
			Mark N. Lampert
By:	BVF Partners L.P., its manager		President
By:	BVF Inc., its general partner
By:	/s/ Mark N. Lampert
	Mark N. Lampert
	President

/s/ Mark N. Lampert

MARK N. LAMPERT

10

EX-99.1

Exhibit 99.1

Biotechnology Value Fund, L.P.

March 30, 2011

Surya N. Mohapatra, Ph.D.

Chairman and Chief Executive Officer

Quest Diagnostics, Inc.

3 Giralda Farms

Madison, NJ 07940

Dear Dr. Mohapatra,

By way of introduction, I am the Founder and General Partner of the Biotechnology Value Fund, L.P. and its affiliates (“BVF”). As you may know, our fund owns, as of our last public filing, a 12% stake in Celera Corp. I am writing to inform you that BVF will not support Quest’s acquisition of Celera, as currently proposed. However, we would like to suggest a revised structure which we believe would enable Quest to acquire the strategic assets it seeks, which BVF would support, which is fair to Celera shareholders, and which we feel has a higher chance of being consummated than the proposed offer.

Specifically, we believe the passive drug royalties which Celera owns, associated with Merck’s Phase 3 osteoporosis drug, Odanacatib, and Pharmacyclics’s Btk, HDAC, and Factor VIIa inhibitors, are extraordinarily valuable, are not of strategic significance to Quest, and are not at all reflected in the proposed purchase price. BVF is willing to support a revised transaction in which these drug royalties are carved out of the acquisition and left with Celera shareholders.

We believe it is in Quest’s self-interest to restructure its offer, and it is the right and fair thing to do. We want to give Quest a chance to agree to do so on a friendly, collaborative basis. This path would engender our full support and would virtually assure that Quest obtains the strategic operating assets that it desires.

The alternative path is for BVF to actively oppose the transaction, the ultimate outcome of which would be unpredictable. At a minimum, our actions would involve the following:

1.  BVF would not tender its shares into Quest’s tender offer for Celera. In addition to withholding our own shares, BVF would encourage all shareholders (many of whom have reached out to us to express their dissatisfaction with the proposed acquisition) to similarly reject the tender offer.

2.  BVF would continue discussions with third parties regarding alternatives to this transaction, including but not limited to the submission of a superior proposal for all or part of the company and/or the replacement of Celera management in order to operate the company independently to maximize shareholder value.

1 Sansome St., 30th Floor, San Francisco, CA 94104 415-288-2395 (Tel.) 415-288-2394 (Fax)

Biotechnology Value Fund, L.P.

3.  In the event that the majority of Celera shares are tendered and the merger is approved, BVF would seek appraisal rights for its full position and, further, would encourage all non-tendering shareholders to join us in allowing an unbiased court to decide the fair value of Celera, including the drug royalties. We believe it is likely that a court will concur with our assessment of the extraordinarily high present value of Celera’s drug royalties. By carving out the drug royalties now, Quest would avoid exposing itself to a judgment liability that could exceed the ultimate monetization of the royalties.

We believe the Quest-Celera transaction is at a critical crossroads that will break decidedly, and potentially irreversibly, in one direction or the other. We sincerely hope Quest elects to pursue a collaborative “win-win” path forward, but we are prepared for the alternative. Please note that we plan to make a public filing of this letter early next week.

Thank you for considering our perspective in this matter.

Sincerely,

/s/ Mark Lampert

Mark Lampert

1 Sansome St., 30th Floor, San Francisco, CA 94104 415-288-2395 (Tel.) 415-288-2394 (Fax)

EX-99.2

Exhibit 99.2

Quest Diagnostics Incorporated

3 Giralda Farms Madison, NJ 07940 973.520.2170 973.520.2142 FAX www.questdiagnostics.com Surya N. Mohapatra, Ph.D. Chairman & Chief Executive Officer

April 1, 2011

Mark Lampert, General Partner

Biotechnology Value Fund, L.P.

1 Sansome Street, 30th Floor,

San Francisco, California 94104

Thank you for your letter dated March 30, 2011.

As we disclosed in the Offer to Purchase filed with the Securities and Exchange Commission on Monday, March 28, our all cash $8 per share transaction reflected in the Merger Agreement and Offer to Purchase is Quest Diagnostics’ best and final offer for the Celera shares.

As you will have also seen from the disclosure in Celera’s Schedule 14D-9, also filed on Monday, Celera engaged in a lengthy process before deciding to execute the Merger Agreement with Quest Diagnostics, during which it explored many alternatives to provide value to its stockholders, including transactions that would separately value its drug assets. At the end of this process, the Celera directors determined that none of these alternatives was reasonably likely to create greater value for Celera’s stockholders, and that the transaction with Quest Diagnostics is fair to, and in the best interests of, Celera’s stockholders.

While you and all other Celera stockholders are, of course, free to make any investment decision you choose, we hope that you will ultimately conclude, as Celera’s directors did, that our offer is fair to and in the best interests of Celera stockholders.

Very truly yours,

/s/ Surya N. Mohapatra

Surya N. Mohapatra